AbbVie Inc. (ABBV): Share Repurchases
$980.00M
Year ended 2025-12-31
$1.50B
Trailing 12 months to 2026-06-30
-13.0%
3-year compound annual growth
0.0%
5-year compound annual growth
-18.5%
10-year compound annual growth
| Period ended | Share Repurchases | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $980.00M | -42.6% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $1.71B | -13.4% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $1.97B | +32.6% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $1.49B | +59.2% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $934.00M | -4.5% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $978.00M | +55.5% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $629.00M | -94.8% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $12.01B | +752.1% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $1.41B | -76.6% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $6.03B | -20.5% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $7.59B | n/m | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $665.00M | n/c | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $320.00M | n/a | 2016-02-19, From 2013-01-01 |
Share Repurchases at similar companies
| Company | Year ended | Share Repurchases | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $980.00M | -42.6% |
| Pfizer Inc (PFE) | 2024-12-31 | $0 | n/a |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $5.08B | +289.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $4.11B | +64.3% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $0 | n/a |
| Abbott Laboratories (ABT) | 2025-12-31 | $893.00M | -31.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $5.95B | +144.8% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $3.44B | +32.1% |
| Viatris Inc (VTRS) | 2025-12-31 | $500.50M | +100.2% |
Compare ABBV, PFE, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗